European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours (2024) Lamarca A, Bartsch DK, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, Rinke A, et al. Journal article European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma (2023) Sorbye H, Grande E, Pavel ME, Tesselaar M, Fazio N, Reed NS, Knigge U, et al. Journal article Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022 (2023) Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, et al. Journal article Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (2023) Dureja S, McDonnell M, Van Genechten D, Bouvier C, Kolarova T, O'Toole D, Singh H, et al. Journal article, Review article High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent (2022) Merola E, Perren A, Rinke A, Zerbi A, Mcnamara MG, Arsenic R, Fazio N, et al. Journal article Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients (2022) Cives M, Hernando J, Lamarca A, Bouvier C, Caplin M, Pavel ME Journal article Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome (2022) Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel ME Journal article, Review article Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results (2021) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Thanh TXM, et al. Conference contribution Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Conference contribution